Lipoxygenases in chronic liver diseases: current insights and future perspectives

被引：7

作者：

Heinrich, Lena ^{[1
]}

Booijink, Richell ^{[1
]}

Khurana, Amit ^{[1
,2
,3
]}

Weiskirchen, Ralf ^{[2
]}

Bansal, Ruchi ^{[1
]}

机构：

[1] Univ Twente, Fac Sci & Technol, Tech Med Ctr, Dept Med Cell BioPhys,Translat Liver Res, NL-7500 AE Enschede, Netherlands

[2] Rhein Westfalische TH RWTH Univ Hosp Aachen, Inst Mol Pathobiochem Expt Gene Therapy & Clin Ch, D-52074 Aachen, Germany

[3] Indian Inst Technol IIT, Ctr Biomed Engn CBME, New Delhi 110016, India

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2022年 / 43卷 / 03期

关键词：

NONALCOHOLIC STEATOHEPATITIS; INSULIN-RESISTANCE; LINOLEIC-ACID; FATTY-ACIDS; INJURY; METABOLITES; CELLS; MICE; INHIBITION; RECEPTOR;

D O I：

10.1016/j.tips.2021.12.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways - 5-, 12-, and 15-LOX - and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.

引用

页码：188 / 205

页数：18

共 50 条

[21] Bisphenol A and human chronic diseases: Current evidences, possible mechanisms, and future perspectives
Rezg, Raja
El-Fazaa, Saloua
Gharbi, Najoua
Mornagui, Bessem
ENVIRONMENT INTERNATIONAL, 2014, 64 : 83 - 90
[22] The role of the gut microbiome in chronic liver diseases: Present insights and future outlook
Lu Jiang
Jian-Gao Fan
Hepatobiliary&PancreaticDiseasesInternational, 2023, 22 (05) : 441 - 443
[23] The role of the gut microbiome in chronic liver diseases: Present insights and future outlook
Jiang, Lu
Fan, Jian-Gao
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (05) : 441 - 443
[24] Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives
Paratore, Mattia
Santopaolo, Francesco
Cammarota, Giovanni
Pompili, Maurizio
Gasbarrini, Antonio
Ponziani, Francesca Romana
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
[25] Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives
Vimalesvaran, Sunitha
Vajro, Pietro
Dhawan, Anil
HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 873 - 883
[26] Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction
Sarah Lechner
Matthew Yee
Berkeley N. Limketkai
Edward A. Pham
Digestive Diseases and Sciences, 2020, 65 : 897 - 905
[27] Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction
Lechner, Sarah
Yee, Matthew
Limketkai, Berkeley N.
Pham, Edward A.
DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (03) : 897 - 905
[28] Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives
Siafaka, Panoraia
Ipekci, Esra
Caglar, Emre Sefik
Okur, Neslihan Ustundag
Buyukkayhan, Derya
MEDENIYET MEDICAL JOURNAL, 2021, 36 (02): : 152 - 162
[29] Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives
Jesper Lindhardsen
Søren Lund Kristensen
Ole Ahlehoff
American Journal of Cardiovascular Drugs, 2016, 16 : 1 - 8
[30] Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives
Lindhardsen, Jesper
Kristensen, Soren Lund
Ahlehoff, Ole
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2016, 16 (01) : 1 - 8

← 1 2 3 4 5 →